FDA would like to have a new “special medical use” category for drugs that could be approved based on a small clinical development program and that would have a limited indication for specific populations.
The impetus for, and initial focus of, the program would be antibiotics for drug resistant bacteria, Commissioner Margaret Hamburg and Center for Drug Evaluation and Research Director Janet Woodcock told...